Substance and claimed effects

Iron deficiency without anemia (IDWA), also called iron-deficient non-anemic (IDNA) or latent iron deficiency, denotes a depletion of body iron stores in an adult whose hemoglobin remains within the reference range. Operationally, the condition is detected through low serum ferritin (the validated proxy for storage iron) and, in inflammatory states or when ferritin is borderline, a low transferrin saturation. Iron deficiency progresses through stages: storage iron is depleted first (ferritin falls), tissue iron supply contracts next (transferrin saturation falls, soluble transferrin receptor rises), and only then does erythropoietic iron fall enough to drop hemoglobin into anemic territory Camaschella 2015. IDWA is the second phase — clinically silent on a complete blood count, biochemically and physiologically active.

This entry covers IDWA in non-pregnant adults: who has it, how it is detected, what consequences follow from depleted iron stores when hemoglobin is normal, and how it is treated. Claimed and evidenced consequences in scope: persistent unexplained fatigue, reduced submaximal exercise capacity, restless legs syndrome, chronic telogen effluvium (diffuse hair shedding), measurable changes in attention and memory, and a contribution to depressive symptoms in some women of reproductive age. Pregnancy and iron-deficiency anemia proper are out of scope. Hereditary hemochromatosis is named only as a contraindication.

Evidence by addressing question

Mechanism

Iron sits at the catalytic centre of dozens of proteins beyond hemoglobin: myoglobin in muscle, cytochromes of the mitochondrial electron transport chain, ribonucleotide reductase in DNA synthesis, thyroid peroxidase, and the iron-dependent monooxygenases that synthesise dopamine, noradrenaline, and serotonin Camaschella 2015. When stored iron is depleted but red blood cell production is still being prioritised, these other iron-requiring systems run on tightening supply.

The clinically observable effects of IDWA map onto these non-erythroid iron pools. Mitochondrial cytochromes drop, oxidative phosphorylation in muscle is impaired, and submaximal endurance suffers before maximal oxygen uptake does Pasricha et al. 2014. Striatal dopaminergic signalling — particularly the D2 receptor — depends on iron as a cofactor for tyrosine hydroxylase; brain iron deficiency is the leading mechanistic explanation for restless legs syndrome, which can occur with normal serum iron status because the blood–brain barrier maintains brain iron semi-independently Allen et al. 2018. Anagen-phase hair follicles depend on iron-containing ribonucleotide reductase for the rapid DNA synthesis of matrix keratinocytes; chronic iron depletion shifts follicles prematurely into telogen, producing diffuse shedding three months after the deficit takes hold.

The hepcidin–ferroportin axis governs iron flux. Hepcidin, produced by the liver, blocks iron export from enterocytes and macrophages by binding ferroportin Camaschella 2015. In iron deficiency, hepcidin falls and intestinal absorption rises — but this same axis explains why oral iron dosing is inefficient: a single dose >40 mg elemental iron raises serum hepcidin for 24+ hours, sharply lowering absorption of any further dose given within that window Moretti et al. 2015.

Evidence

Direct randomised evidence that correcting IDWA produces real-world benefit comes from four mature lines of work.

Fatigue. The 2012 multicentre Vaucher RCT in 198 menstruating women with unexplained fatigue and ferritin <50 µg/L randomised to 80 mg/day oral ferrous sulfate or placebo for 12 weeks reduced fatigue scores by ~50% from baseline in the iron arm versus ~19% in placebo, a between-group difference clearly favouring iron Vaucher et al. 2012. The earlier Krayenbuehl RCT used a single intravenous dose of iron sucrose (800 mg) in 90 fatigued non-anemic premenopausal women with ferritin ≤50 ng/mL and found significant fatigue reduction, with effect most pronounced in women whose baseline ferritin was ≤15 ng/mL Krayenbuehl et al. 2011. The Yokoi & Konomi meta-analysis pooled six RCTs and found a statistically significant standardised mean effect of iron on fatigue of 0.33 (95% CI 0.17–0.48; p<0.0001) in non-anemic iron-deficient adults — modest in absolute terms but reproducible across trials Yokoi & Konomi 2017.

Exercise performance. The Pasricha meta-analysis of iron supplementation trials in women of reproductive age (most participants were iron-deficient non-anemic) found a significant improvement in maximal exercise performance and a meaningful improvement in submaximal endurance metrics, with iron raising VO₂max and reducing time to exhaustion Pasricha et al. 2014. The signal is strongest at submaximal intensities, consistent with the mitochondrial-cytochrome mechanism (oxidative phosphorylation matters more at sub-VO₂max workloads than at peak oxygen delivery).

Restless legs syndrome. The Trenkwalder 2017 randomised trial gave a single 1000-mg infusion of ferric carboxymaltose to 110 RLS patients with serum ferritin <75 µg/L (or 75–300 µg/L with TSAT <20%) and a normal hemoglobin; the iron arm improved on the International Restless Legs Syndrome Severity Scale, reaching statistical significance by week 12 Trenkwalder et al. 2017. The IRLSSG task force guideline formalises iron as first-line treatment for clinically significant RLS at ferritin ≤75 µg/L or TSAT <20% — a threshold meaningfully higher than the general iron-deficiency cutoff, because brain iron requirements run ahead of body stores in RLS Allen et al. 2018.

Cognition. The Murray-Kolb & Beard 16-week randomised supplementation trial in 113 young women found that iron-deficient (with or without anemia) participants performed worse on attention, memory and learning tasks at baseline, and that improvement in serum ferritin after iron treatment correlated with improvement in cognitive task accuracy Murray-Kolb & Beard 2007. The signal in non-anemic iron deficiency is more modest than in frank anemia but present.

Hair. Evidence here is observational and uneven. Cross-sectional studies consistently find lower serum ferritin in women with chronic telogen effluvium than in controls, and case series report regrowth with iron repletion in deficient women — but the relationship in female pattern hair loss specifically is not consistent across studies, and a randomised trial of iron repletion versus placebo in telogen effluvium with documented IDWA is conspicuously missing. Clinical dermatology guidance treats ferritin <30–40 µg/L as a correctable contributor to diffuse shedding while not claiming iron repletion alone reverses non-iron-related shedding.

Protocol

Detection is a blood test ordered by a primary care clinician: serum ferritin is the dominant marker, paired with transferrin saturation when ferritin is borderline or when inflammation may falsely elevate ferritin. Guideline thresholds have converged on serum ferritin ≤30 ng/mL in the absence of inflammation for diagnosing iron deficiency in non-pregnant adults Iolascon et al. 2024. Older labs and many regional reference ranges still flag iron deficiency only at ferritin <15 µg/L, which under-diagnoses substantially; physiologically derived thresholds in NHANES data suggest a true cutoff closer to 25–30 µg/L for non-pregnant women and adolescents Weyand et al. 2023. For RLS specifically, the treatment threshold is ferritin ≤75 µg/L or TSAT <20% Allen et al. 2018.

Treatment is oral iron in nearly all cases. The classic regimen is ferrous sulfate 65 mg elemental iron once daily, taken on an empty stomach with vitamin C, for 3 months and then re-checked. The Moretti and Stoffel work showed that daily and twice-daily dosing both raise serum hepcidin enough to suppress absorption of the next dose, while alternate-day single-morning dosing increases fractional absorption (~22% vs ~16% for consecutive-day in iron-depleted women) and roughly halves GI side effects Moretti et al. 2015 Stoffel et al. 2017. The IRLSSG guideline endorses once-daily over twice-daily oral dosing explicitly on this basis Allen et al. 2018. Intravenous iron (ferric carboxymaltose, iron sucrose, iron derisomaltose) is reserved for malabsorption, intolerance of oral iron, ongoing blood loss exceeding oral repletion capacity, or RLS where rapid response matters.

Re-test ferritin at 3 months. Hemoglobin tracks first; ferritin (the stored iron pool) refills over 3–6 months and often needs a longer course than people expect.

Contraindications

The dominant contraindication is hereditary hemochromatosis, the autosomal recessive iron-overload disorder driven primarily by HFE C282Y homozygosity in people of Northern European ancestry (~1 in 200 in that population). Iron supplementation accelerates organ damage in undiagnosed hemochromatosis. Pre-supplementation iron studies — ferritin and TSAT — catch most homozygotes who have begun to load iron: a TSAT >45% with elevated ferritin in a man over 40 warrants HFE testing rather than empirical iron supplementation. Active infection raises hepcidin and blunts absorption; iron is typically deferred until acute infection resolves. Patients on disease-modifying treatment for inflammatory bowel disease, on dialysis, or with congestive heart failure are typically managed by their specialists with IV iron rather than oral.

Misconceptions

The most consequential misconception is that a normal hemoglobin rules out iron-related symptoms. Hemoglobin is the last iron-dependent pool to fall: by the time it is anemic, the patient has been running on depleted stores for months or years Camaschella 2015. A complete blood count alone misses IDWA entirely. The second misconception is that ferritin's normal range starts at 15 or 20 ng/mL — these lab reference ranges were derived from population distributions that include large fractions of iron-deficient menstruating women; physiologically based thresholds put the cutoff substantially higher Weyand et al. 2023 Iolascon et al. 2024. The third is that men with low iron should simply take iron — in men and post-menopausal women, IDWA is unusual enough that occult gastrointestinal blood loss is the working diagnosis until proven otherwise, and iron treatment without a search for the source can mask a colorectal cancer.

Audience

The population in whom IDWA dominates is menstruating women, particularly with heavy menstrual bleeding, pregnancy histories within the prior year, restrictive or plant-based eating, regular blood donation, or endurance training. NHANES 2003–2020 analysed by Weyand et al. found ferritin <25 µg/L in 38.6% of US females aged 12–21, against an iron-deficiency-anemia prevalence of only 6.3% in the same cohort — a five-to-six-fold gap between IDWA and IDA in this group Weyand et al. 2023. Black and Hispanic adolescents and women in food-insecure households are disproportionately affected.

The other recognised at-risk populations: endurance athletes (foot-strike haemolysis, GI micro-bleeding, hepcidin spikes from exercise-induced inflammation), regular blood donors (each whole-blood donation removes ~200 mg iron, and donors typically take 6+ months to replenish), people who have undergone bariatric surgery (gastric acid is required for non-heme iron absorption), and patients with celiac disease, atrophic gastritis, or H. pylori. In men and post-menopausal women without a clear cause, IDWA is sufficiently unusual that GI evaluation is the standard workup.

Failure modes

The two failure modes in primary care are under-detection and under-treatment. Under-detection comes from clinicians ordering a CBC for fatigue, finding normal hemoglobin, and not adding ferritin; the menstruating-woman patient leaves with "everything's normal" while ferritin sits at 8 µg/L. Under-treatment comes from prescribing iron for too short a course — a 6-week course of ferrous sulfate may correct mild anemia but rarely refills storage iron, and the patient's symptoms return three months later. The third failure mode is patient-driven: GI side effects (nausea, constipation, dark stools, metallic taste) drive abandonment of treatment in 30–50% of patients on conventional daily dosing; alternate-day single-morning dosing addresses this directly Stoffel et al. 2017.

Practicalities

Ferritin is a cheap, commodity blood test — added to a standard fatigue workup it costs the patient little. In jurisdictions where the patient orders their own labs (US direct-to-consumer testing, UK private), a ferritin plus iron panel runs $20–40. Ferrous sulfate 325 mg (65 mg elemental iron) is an over-the-counter generic supplement, ~$5–10 for a 3-month course. Ferrous bisglycinate and ferrous fumarate are alternatives marketed as better-tolerated; the evidence for substantially fewer GI effects is real for bisglycinate but the price premium is meaningful. Intravenous iron infusion in a clinic costs $300–2,500 depending on formulation and insurance, but resolves repletion in 1–2 visits.

Stakes

Untreated IDWA in a menstruating woman tends not to self-correct — menstrual blood loss continues to draw down stores faster than dietary iron replenishes them. The unaddressed condition can persist for years, with the fatigue, exercise intolerance, possible cognitive blunting, and possible hair shedding accumulating as the "just my baseline" felt experience. Progression to overt iron-deficiency anemia adds breathlessness, palpitations and the classic pallor; in pregnancy, untreated maternal iron deficiency raises low-birthweight risk and may impair offspring neurodevelopment. In RLS, untreated IDWA permits the syndrome to worsen and dopaminergic medication augmentation to take hold.

Payoff

The most striking finding across the iron-supplementation literature in IDWA is the magnitude of the fatigue response — roughly half of the Vaucher and Krayenbuehl cohorts experienced clinically meaningful fatigue reduction within 6–12 weeks Vaucher et al. 2012 Krayenbuehl et al. 2011. Submaximal exercise capacity improves over weeks Pasricha et al. 2014. RLS symptoms improve over 12 weeks following IV repletion Trenkwalder et al. 2017. Hair regrowth from telogen effluvium, where iron is the operative cause, takes 3–6 months because the hair cycle itself is long.

History

The concept of iron deficiency without anemia has had practical recognition since the mid-twentieth century but was formally separated from frank IDA in the haematology literature in the 1980s and 1990s, with ferritin's introduction as a clinical lab assay (1972) providing the diagnostic tool. The clinical-trial literature on IDWA specifically — fatigue, exercise, RLS, cognition — has matured since approximately 2007. The 2024 HemaSphere recommendations and the 2024 American Society of Hematology draft guidelines formalised the ferritin ≤30 µg/L threshold for diagnosis Iolascon et al. 2024.

Out of scope

Iron-deficiency anemia proper, iron deficiency in infancy and early childhood, iron deficiency in pregnancy (different thresholds, different stakes, different treatment options), the management of anemia of inflammation, and hereditary hemochromatosis. Heart-failure iron deficiency is mentioned only to flag that its diagnostic thresholds differ.

Credibility range

Optimist case

IDWA is one of the few unrecognised and under-treated reversible causes of fatigue, restless legs, hair shedding and possibly depression in a substantial fraction of menstruating adults. A simple, cheap blood test detects it; a cheap, over-the-counter supplement corrects it over 3 months; randomised trials in non-anemic women have shown ~50% fatigue reduction. The 38.6% prevalence figure in young US females Weyand et al. 2023, combined with routine clinical practice that ignores ferritin until hemoglobin drops, means there is a large reservoir of people whose felt-experience baseline could be raised meaningfully by a $5 supplement plus 12 weeks of patience. The dopamine-RLS mechanism is well-established Allen et al. 2018, the mitochondrial-exercise mechanism likewise Pasricha et al. 2014. The case for routinely ordering ferritin in any menstruating adult presenting with unexplained fatigue is strong.

Skeptic case

Several of the IDWA effect sizes are modest, and the placebo response in fatigue trials is large. The Yokoi & Konomi pooled effect on fatigue of 0.33 is statistically robust but a small-to-moderate standardised effect Yokoi & Konomi 2017. The Krayenbuehl IV trial achieved significance principally in the ferritin ≤15 µg/L subgroup Krayenbuehl et al. 2011, suggesting the response above ferritin 15 is weaker than the headline number implies. The hair-loss link in chronic telogen effluvium is observational and contested. The cognition signal in IDWA-only (excluding anemic participants) is modest. There is also a real risk of over-diagnosis: raising the ferritin cutoff to 30 or 45 ng/mL makes the prevalence rise from ~11% to ~48% in primary care populations, and not every person flagged that way has a felt-symptom load that supplementation will lift. And iron is not harmless — GI tolerability is poor and undetected hemochromatosis is genuinely dangerous.

Author's call

The evidence is strong enough to make routine ferritin testing in any fatigued menstruating adult a clear win — the test is cheap, the treatment is cheap, the fatigue response in confirmed IDWA cases is reliably real (not transformative for everyone, but reliably real for many), and the RLS evidence in particular is solid. The case in non-menstruating populations is much weaker, both because IDWA is rarer and because the underlying cause (typically GI bleeding) needs the diagnostic workup more than the supplement. The author's call lands on the optimist side, with the caveats baked in: confirm with a lab, supplement at the conservative dose with alternate-day dosing, re-test at 3 months, and refer for GI workup if the patient is male or post-menopausal. Evidence rating of 4: multiple RCTs, consistent mechanism, formal guideline (IRLSSG) on the RLS arm, recent ASH/HemaSphere diagnostic guideline; held back from 5 by modest pooled effect sizes outside the RLS context and remaining disagreement on optimal ferritin thresholds.

Stakeholder and incentive map

• Patients pushing for recognition: menstruating women with fatigue who feel under-served by "your bloodwork is normal" responses; online communities around chronic fatigue, RLS, and hair loss are vocal about ferritin testing.
• Clinicians under-detecting: primary care often relies on the CBC and treats hemoglobin as the iron gate; ferritin is an add-on order, frequently omitted. Time-pressured visits and ingrained reference ranges work against detection.
• Hematology / hematologic societies: ASH, EHA, HemaSphere have been actively revising guidance toward ferritin ≤30 µg/L and acknowledging the IDWA gap Iolascon et al. 2024.
• Sleep / RLS specialists: IRLSSG has been ahead of general internal medicine on iron status as a treatable contributor to RLS Allen et al. 2018.
• Commercial supplement industry: oral iron is a low-margin commodity but newer formulations (sucrosomial, bisglycinate, liposomal) are marketed at premium prices on tolerability claims with mixed direct comparative evidence.
• IV iron manufacturers: commercial pressure to expand IV iron indications beyond clear oral-iron-failure contexts; ferric carboxymaltose has notable revenue at stake.
• Blood services: regular donors are a known at-risk group; some services now monitor donor ferritin, others don't.

Population variability

• Sex and reproductive status. Menstruating women are at dramatically higher risk than men or post-menopausal women. Pregnancy raises requirements further (out of scope here).
• Age. Adolescents and young adults under 25 in the menstruating population have the highest US prevalence — partly because of growth-related iron demands, partly because clinical visits and screening are infrequent in this group Weyand et al. 2023.
• Race/ethnicity. US NHANES analyses consistently find higher IDWA prevalence in non-Hispanic Black and Hispanic women than in non-Hispanic white women, with food insecurity contributing.
• Diet. Strict vegetarian and vegan diets rely entirely on non-heme iron, which is roughly an order of magnitude less bioavailable than heme iron. Risk is moderately elevated in plant-based eaters who do not pair iron-rich foods with vitamin C or who consume high tea/coffee polyphenol loads with meals.
• Athletic load. Endurance athletes, particularly female endurance athletes, run a higher prevalence due to foot-strike haemolysis, sweat losses, GI micro-bleeding, and exercise-induced hepcidin elevations.
• Donation. Frequent blood donors deplete iron stores faster than diet replenishes; ferritin should be checked in donors who give more than 3–4 times yearly.
• GI conditions. Celiac disease, autoimmune atrophic gastritis, H. pylori, post-bariatric anatomy and chronic NSAID use all impair absorption or increase losses.
• Genetics. Iron-refractory iron-deficiency anemia (TMPRSS6 mutations) is rare but worth flagging in patients who don't respond to repletion.

Knowledge gaps

The largest gap is the optimal ferritin threshold for symptom-driven treatment versus for population screening — the literature is converging on ≤30 µg/L for diagnosis but the threshold at which iron repletion produces a clinically meaningful response is plausibly closer to ≤15 µg/L in some symptom domains and closer to ≤75 µg/L in RLS specifically Krayenbuehl et al. 2011 Allen et al. 2018. The hair-loss link in chronic telogen effluvium lacks a randomised iron-repletion trial despite years of clinical observation. The mood-and-depression signal needs RCTs in IDWA-only populations rather than mixed IDA/IDWA cohorts. The optimal oral dosing regimen for typical IDWA — daily versus alternate-day versus thrice-weekly — has only short-duration absorption studies; long-term comparative effectiveness on ferritin recovery and symptom relief is sparse. And whether routine ferritin screening of asymptomatic menstruating adults would justify itself on population-health terms remains an open USPSTF question.

Scope and brief alignment. The topic brief named energy, exercise capacity, hair, restless legs, and cognition as effects worth covering. The article covers all five: energy and exercise via the evidence and payoff sections, restless legs as a recurring thread through evidence / protocol / payoff (and reflected in the sleep score), hair shedding in the cumulative-beauty score and the payoff / stakes prose, and cognition via the Murray-Kolb & Beard line in the evidence section. Mood is scored modestly (2) on the basis of NHANES cross-sectional associations and plausible mechanism (iron-dependent monoamine synthesis), with explicit acknowledgement in the research dossier that IDWA-only RCT evidence on mood is thinner than for fatigue.

Hard scoping calls.

• Iron-deficiency anemia proper is out of scope — it is its own diagnostic and treatment territory and warrants a separate entry once the catalogue covers it. The entry deliberately does not blur into IDA.
• Pregnancy iron requirements are out of scope: thresholds differ, the trial literature is largely separate, and the USPSTF is mid-revision on pregnancy screening. Worth its own entry.
• Hereditary hemochromatosis is named only as a contraindication and as the inverse problem. The entry resists conflating "low iron is common" with "everyone should supplement" — pre-treatment ferritin + TSAT catches the at-risk hemochromatosis pattern in men over 40 and post-menopausal women.
• Heavy menstrual bleeding is named in out-of-scope as the upstream cause for most premenopausal cases. A future entry on HMB and the IUS / tranexamic acid options would close this loop.

Rating difficulties.

• Energy (4) vs (5): the fatigue evidence in confirmed IDWA is the strongest single signal, but the Yokoi & Konomi pooled SMD of 0.33 is small-to-moderate, and Krayenbuehl's IV trial reached significance principally in the ferritin ≤15 ng/mL subgroup. The lift is reliable in confirmed cases but not transformative across the whole non-anemic-iron-deficient population. Landed at 4 rather than 5.
• Sleep (3): justified entirely through restless legs syndrome, not through generic sleep-quality lift. The RLS evidence is strong (Trenkwalder RCT, IRLSSG guideline). For readers without restless legs the score won't translate; this is acknowledged in the body and editor-notes-side rather than over-scored.
• Beauty cumulative (2): ferritin correlates with chronic telogen effluvium in observational and case-series data, but a randomised iron-repletion trial in CTE specifically is missing. Conservative.
• Audience scoping: deliberately left at "applies to everyone" rather than gender-scoping to female. The condition's prevalence is dramatically higher in menstruating women, but it does occur in men and post-menopausal women — where it triggers a different (and important) diagnostic pathway (GI workup), which the entry covers explicitly. Scoping the entry to women would hide that.

Future link candidates (entries that don't yet exist):

• Heavy menstrual bleeding — the upstream cause for most premenopausal IDWA. Cross-link target once authored.
• Hereditary hemochromatosis — the inverse problem; the contraindication callout would benefit from a direct link.
• Blood donation and donor iron monitoring — flagged as a risk population but no entry exists.
• Restless legs syndrome — would carry the RLS-specific iron protocol in more depth than fits here.
• Iron in pregnancy — different thresholds, different stakes.

Citation note. The dossier carries Pasricha 2014, Camaschella 2015, MurrayKolb 2007, YokoiKonomi 2017, Iolascon 2024 and Weyand 2023 as load-bearing; the article uses a subset of these plus Vaucher 2012, Krayenbuehl 2011, Trenkwalder 2017, Allen 2018, Moretti 2015, Stoffel 2017. Bibliography in the research dossier is a superset of what the article surfaces.